uniQure (QURE)
(Real Time Quote from BATS)
$4.73 USD
-0.03 (-0.63%)
Updated May 28, 2024 10:18 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
uniQure N.V. [QURE]
Reports for Purchase
Showing records 41 - 60 ( 153 total )
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Thoughts Post-LSD KOL Dinner; Bottom line - It?s AAV?s Over Lenti?s
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
AMT-130 Enrollment Criteria No Longer a Bottleneck
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Bringing a Wallet to a Hammer and Sickle Fight, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Expression Loss Despite Tacrolimus Implies FLT180a Is Not Entitled to Throw Shade on AMT-061
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Our Thoughts on AMT-130 Phase 1/2 Inclusion Criteria
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Potential Insights Into the Effects of Wild-Type HTT Knockdown
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
No Surprises With AMT-061, Durability With Gen-1 AMT-060 Now Approaching Four Years
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Getting Some Mojo Back; Updates Post 3Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
HD Program Appears to Be up and Running and a Recent Hem- B Population-Based Survey Points to a Higher Prevalence
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Hem B: Has PFE Got What it Takes to Clot? We Think Not
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
uniQure 2Q19 Update With a Focus on AMT-130
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Hem B Clinical Match-up Appears Settled in Favor of uniQure; Hem A Is Where the Action Is
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
Company: uniQure N.V.
Industry: Medical - Biomedical and Genetics
AMT-061 Gradually Transforming Hemophilia B Into a Winner-Take-All Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D